Resumen

BENITO-GARCIA, Filipe; GASPAR, Ângela; MOTA, Inês  y  MORAIS-ALMEIDA, Mário. Sublingual latex immunotherapy and allergenic profile study - 3 cases. Rev Port Imunoalergologia [online]. 2019, vol.27, n.2, pp.157-164. ISSN 0871-9721.  https://doi.org/32932/rpia.2019.07.014.

Latex allergy affects selected populations, called high-risk groups. Latex sensitization profile differs between these risk groups. The commercially available sublingual latex immunotherapy (SLIT) extract is mostly constituted by Hev b 6 and Heb b 5 proteins. We described three clinical cases of patients with latex anaphylaxis (two also with anaphylaxis in the context of latex-fruit syndrome) who were successfully submitted to SLIT. In all cases, occurred clinical amelioration (two asymptomatic in contact with latex) and negative or marked reduction in specific IgE levels for latex and major recombinant allergens (rHev b 5 and rHev b 6). No new sensitizations were detected to recombinant latex-allergens after a course of SLIT with at least 3 years duration. The SLIT recommendation is made according to latex sensitization profile, which must always be evaluated before latex immunotherapy’s decision in order to achieve a successful desensitization. This therapeutic option has proved to be effective and safe for the management of these patients, with an improvement in the patient’s quality of life.

Palabras clave : Latex allergy; latex-fruit syndrome; recombinant allergens; specific imunotherapy.

        · resumen en Portugués     · texto en Portugués     · Portugués ( pdf )